Researcher:
Rızalar, F. Sıla

Profile Picture
ORCID

Job Title

Other

First Name

F. Sıla

Last Name

Rızalar

Name

Name Variants

Rızalar, F. Sıla
Rızalar, Filiz Sıla

Email Address

Birth Date

Filters

20161

Advanced Search

Filter by

Settings

Researcher Of Publications: search.filters.isAuthorOfPublication.74c5f239-b3cc-446e-9ab2-611179d6204c

Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    PublicationOpen Access
    Anti-inflammatory modulation of microglia via CD163-targeted glucocorticoids protects dopaminergic neurons in the 6-OHDA Parkinson's disease model
    (Society for Neuroscience, 2016) Tentillier, Noemie; Etzerodt, Anders; Olesen, Mads N.; Jacobsen, Jan; Bender, Dirk; Moestrup, Soren K.; Romero-Ramos, Marina; Department of Molecular Biology and Genetics; Rızalar, F. Sıla; Department of Molecular Biology and Genetics; Graduate School of Sciences and Engineering
    Increasing evidence supports a decisive role for inflammation in the neurodegenerative process of Parkinson's disease (PD). The immune response in PD seems to involve, not only microglia, but also other immune cells infiltrated into the brain. Indeed, we observed here the infiltration of macrophages, specifically CD163+ macrophages, into the area of neurodegeneration in the 6-hydroxydopamine (6-OHDA) PD model. Therefore, we investigated the therapeutic potential of the infiltrated CD163+ macrophages to modulate local microglia in the brain to achieve neuroprotection. To do so, we designed liposomes targeted for the CD163 receptor to deliver dexamethasone (Dexa) into the CD163+ macrophages in the 6-OHDA PD model. Our data show that a fraction of the CD163-targeted liposomes were carried into the brain after peripheral intravenous injection. The 6-OHDA-lesioned rats that received repeated intravenous CD163-targeted liposomes with Dexa for 3 weeks exhibited better motor performance than the control groups and had minimal glucocorticoid-driven side effects. Furthermore, these animals showed better survival of dopaminergic neurons in substantia nigra and an increased number of microglia expressing major histocompatibility complex II. Therefore, rats receiving CD163-targeted liposomes with Dexa were partially protected against 6-OHDA-induced dopaminergic neurodegeneration, which correlated with a distinctive microglia response. Altogether, our data support the use of macrophages for the modulation of brain neurodegeneration and specifically highlight the potential of CD163-targeted liposomes as a therapeutic tool in PD.